<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470951</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-179</org_study_id>
    <nct_id>NCT00470951</nct_id>
  </id_info>
  <brief_title>Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer</brief_title>
  <acronym>CTS-179</acronym>
  <official_title>A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed the randomized prospective trial of comparing open and
      laparoscopic resection in locally advanced rectal cancer after preoperative chemoradiation in
      order to determine the oncologic and functional efficacy of laparoscopic rectal resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Title: A comparison for laparoscopically assisted and open surgery for advanced rectal
           cancer after preoperative chemoradiation - randomized prospective trial

        2. Principal investigator: Jae Hwan Oh Co-investigator: Seung Yong Jeong, Sung Bum Kang,
           Hyo Seong Choi, Seok-Byung Lim

        3. Purpose of the study: To compare efficacy of laparoscopic and open resection for locally
           advanced rectal cancer after preoperative chemoradiation

        4. Specific aims

             1. comparison of oncologic outcomes

             2. comparison of quality of life

             3. comparison of anorectal function

        5. Materials Rectal cancer &lt;9cm from anal verge, measured by rigid sigmoidoscopy
           histologically proven adenocarcinoma locally advanced (T3), determined by CT,
           transrectal ultrasonography, MRI without any contraindication for general
           anesthesia,operation and chemoradiation Completion of preoperative chemoradiation

        6. Statistics

             1. Sample size calculation for non-inferiority trial: 340

             2. Disease free survival: Log-rank test,Cox regression analysis

             3. QOL and anorectal function: Repeated measured ANCOVA

        7. Methods

             1. operation time of operation : 6-8 weeks after end of preoperative chemoradiation
                surgical technique standard total mesorectal excision and high ligation of inferior
                mesenteric vessels

             2. preoperative chemoradiation chemotherapy: 2 cycles of 5-FU (400 mg/m2/day) + LV (20
                mg/m2/day) IV bolus, for 3 days in 1st &amp; 5th wks of RT or Capecitabine 825 mg/m2
                p.o. bid during RT RT:45 Gy/ 25 fractions to the pelvis, 5.4 Gy/ 3 fractions boost
                to the primary tumor over 5.5 wks

             3. postoperative chemotherapy 4 cycles of 5-FU (400 mg/m2/day) + LV (20 mg/m2/day) IV
                bolus, for 5 days, 4 wks interval

             4. oncologic outcomes

                  1. Short-term outcomes Surgical length of incision op time blood loss
                     intraoperative complications conversion rate Pathological resection margins
                     (proximal, distal, circumferential) number of harvested lymph nodes length of
                     resected bowel tumor regression grade (Dworak's grading) TNM staging
                     Perioperative recovery duration of use of parenteral narcotics initiation of
                     peristalsis initiation of oral intake duration of hospital stay 30-day
                     postoperative mortality morbidity

                  2. Long-term outcomes Primary end point Disease free survival (3 years after
                     surgery) Secondary end points Overall survival Local recurrence Distant
                     metastasis Port-site and wound site recurrence

             5. Quality of life Urinary function Duration of urinary catheterization Residual urine
                volume at discharge International Prostate Symptom Score (IPSS) Male sexual
                function International Index of Erectile Function (IIEF) Female sexual function
                Female Sexual Function Index (FSFI) QOL assessment EORTC QLQ C30 EORTC QLQ CR38

             6. Anorectal function Anorectal manometry Maximum Resting Pressure Maximum Squeezing
                Pressure High Pressure Zone Sphincter Length Sensory Threshold Rectal Capacity
                Rectal Compliance Rectoanal Inhibitory Reflex Fecal Incontinence Severity Index
                (FISI)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anorectal function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year, 5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>preop, postop 3mo, posop 1 yr, 3yr, 5yr</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunologic response</measure>
    <time_frame>preop, postop 2hr, postop 1day, 5day</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>open rectal resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional open resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic rectal resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laparoscopic rectal resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open rectal resection</intervention_name>
    <description>open rectal resection</description>
    <arm_group_label>open rectal resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic rectal resection</intervention_name>
    <description>laparoscopic assisted rectal resection</description>
    <arm_group_label>laparoscopic rectal resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mid to low rectal cancer (within 9cm from AV, measured by RS)

          -  Histologically proven adenocarcinoma

          -  Locally advanced (T3, determined by CT, MRI and TRUS)

          -  Completion of preoperative chemoradiation

          -  Age: 18-80

          -  Hb ≥ 10g/dl, WBC≥ 3,000/mm3, Plt≥ 100,000/mm3

          -  Cr ≤ 1.5 mg/dl

          -  Adequate cardiopulmonary function

          -  Informed consent from patient or patient's relative

        Exclusion Criteria:

          -  Metastasis in liver, lung, brain, bone, paraaortic LN, subclavicular LN, inguinal LN

          -  Second primary malignancy (except CIS of the cervix or adequately treated skin cancer
             or prior malignancy treated more than 5 years ago without recurrence)

          -  Cardiopulmonary dysfunction

          -  Active, uncontrolled infection

          -  Active, uncontrolled psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hwan Oh, M.D., ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Seung Yong Jeong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>laparoscopic assisted resection</keyword>
  <keyword>open resection</keyword>
  <keyword>preoperative chemoradiation</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

